AVI BioPharma Updated Safety Results

March 24, 2010 (FinancialWire) — AVI BioPharma (NASDAQ: AVII) presented updated data on the company's ongoing, open-label, systemic Phase 1b/2 trial of AVI-4658 for the treatment of Duchenne muscular dystrophy (DMD) at the TREAT-NMD / NIH International Conference taking place November 17-19 in Brussels, Belgium. The most recent safety data demonstrate that AVI-4658 has been well tolerated in a dose escalation study that is now enrolling the sixth and final cohort at 20 mg/kg. The maximum cumulative dose administered to date has been updated to 3132 mg, with a maximum single dose reaching 900 mg, with no adverse safety signals in either circumstance.

By way of reference, results presented at the 7th Annual Action Duchenne Conference in October 2009, highlighted that the maximum cumulative dose reached was 2797 mg and the maximum single dose reached was 300 mg, with no safety signals or significant side effects arising in any of the 16 boys treated.

Of note, at the TREAT-NMD / NIH meeting, pre-clinical data was also presented demonstrating that treatment with AVI-4658 was tolerated at dosages up to 960 mg/kg in mice and up to 320 mg/kg in primates, both doses which are feasible in human subjects.

Source: Zangani Investor Community (http://www.investrend.com/about/zangani).

FinancialWire(tm) is committed to serving the financial community through true journalism and providing relevant resources to investors. Standards-based, independent equity research on numerous public companies is available through the Investrend Research Syndicate (http://www.investrend.com/reports) written by FIRST Research Consortium (http://www.investrend.com/FIRST) member-providers. Free annual reports and company filings for companies mentioned in the news are available through the Investrend Information Syndicate (at http://investrend.ar.wilink.com/?level=279). FinancialWire(tm), in cooperation with the Investrend Broadcast Syndicate, also provides complete, daily conference call and webcast schedules as a service to shareholders and investors via the FirstAlert(tm) Network’s “FirstAlert(tm) Daily” (http://www.financialwire.net/news-alerts/).

FinancialWire(tm) is a fully independent, proprietary news wire service. FinancialWire(tm) is not a press release service, and receives no compensation for its news, opinions or distributions. Further disclosure is at the FinancialWire(tm) website (http://www.financialwire.net/disclosures.php). Contact FinancialWire(tm) directly via inquiries@financialwire.net.

Source of original content for this article: (http://www.zangani.com/node/4024).